Proteins, I.e., More Than 100 Amino Acid Residues Patents (Class 530/350)
  • Patent number: 10663475
    Abstract: Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 26, 2020
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Laura Ranum, Tao Zu
  • Patent number: 10660948
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 26, 2020
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • Patent number: 10654934
    Abstract: The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: May 19, 2020
    Assignee: Innovative Cellular Therapeutics Co., Ltd.
    Inventors: Lei Xiao, Zhao Wu, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi
  • Patent number: 10647997
    Abstract: A modified effector cell includes a non-reversibly produced vector-encoded anti-GD2-BB-? chimeric receptor for use in disialoganglioside GD2-expressing neoplasia, which is inserted in the cell, to obtain an effector cell that stably produces the anti-GD2-BB-? chimeric receptor, the chimeric receptor having two distinct mutually fused portions, i.e. an intra-cytoplasmic portion and an extra-cytoplasmic portion.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: May 12, 2020
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Massimo Dominici, Sara Caldrer, Maria Carlotta Spano, Paolo Paolucci, Marco Bestagno, Dario Campana
  • Patent number: 10646347
    Abstract: Osteoconductive synthetic bone grafts are provided in which porous metallic matrices are loaded with an osteoinductive protein. In certain embodiments, the grafts include porous ceramic granules deposited within the matrices.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: May 12, 2020
    Assignee: Bioventus LLC.
    Inventors: Jeffrey Welch, Eric Vanderploeg, Christopher Wilson, John Wozney
  • Patent number: 10646542
    Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: May 12, 2020
    Assignee: Molecular Partners AG
    Inventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
  • Patent number: 10648014
    Abstract: Disclosed are compositions and methods for measuring tyrosine kinase activity using degradation resistant biosensors comprising a reporter sequence, a target sequence, and a transduction sequence. In certain embodiments, the invention includes a biosensor comprising a peptide comprising a reporter sequence, i.e., an amino acid sequence including a tyrosine residue that can be phosphorylated by a tyrosine kinase. In certain embodiments, a biosensor comprises a reporter sequence configured to resist degradation from proteases, a targeting sequence coupled to the reporter sequence and configured to bind to a protein interaction domain of a kinase, and a transduction sequence coupled to the targeting sequence.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: May 12, 2020
    Assignee: Purdue Research Foundation
    Inventors: Laurie L Parker, Robert John Schuster
  • Patent number: 10633712
    Abstract: The technology described herein relates to assays and methods for the diagnosis, prognosis, and/or treatment of melanoma, e.g. relating to measuring the level of neurophilin-2 (NRP-2) mRNA expressed in melanoma cells. In some embodiments, the level of NRP-2 can be normalized to the level of Melan-A (MART) mRNA.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: April 28, 2020
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Rhoda M. Alani, Byungwoo Ryu
  • Patent number: 10626184
    Abstract: In various embodiments the invention provides anti-mucin-like protein (MLP) monoclonal antibodies, compositions and methods for detecting MLP as a biomarker for mucin-secreting type of cancer such as ovarian or pancreatic cancer.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: April 21, 2020
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Hans-Wilhelm Schwaeble, Gregory A. Demopulos
  • Patent number: 10611809
    Abstract: A single-domain antibody (sdAb) is produced by causing a bacteria to express the sdAb into cytoplasm of the bacteria, wherein the sdAb is expressed as a fusion protein with the acid tail of ?-synuclein. In embodiments, the protein is free of a periplasmic location tag. Such antibodies have the unexpected ability to refold after thermal denaturation.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: April 7, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Daniel Zabetakis, George P. Anderson, Ellen R. Goldman, Kendrick Turner, P. Audrey Brozozog Lee
  • Patent number: 10576145
    Abstract: The present invention provides in certain embodiments conjugates comprising at least one CD200 inhibitor and an adjuvant, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a composition comprising a CD200 inhibitor and an adjuvant.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: March 3, 2020
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventor: Michael Olin
  • Patent number: 10577401
    Abstract: A nucleic acid encodes a single-domain antibody (sdAb) is produced by causing a bacteria to express the sdAb into cytoplasm of the bacteria, wherein the sdAb is expressed as a fusion protein with the acid tail of ?-synuclein. In embodiments, the protein is free of a periplasmic location tag. Such antibodies have the unexpected ability to refold after thermal denaturation.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: March 3, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Daniel Zabetakis, George P. Anderson, Ellen R. Goldman, Kendrick Turner, P. Audrey Brozozog Lee
  • Patent number: 10563179
    Abstract: The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: February 18, 2020
    Assignee: University of Washington Through Its Center for Commercialization
    Inventors: Edward Clark, Jay Wesley Chaplin
  • Patent number: 10561705
    Abstract: A peptide comprising SEQ ID NO: 1 (Xaa1-Tyr-Phe-Ala-Tyr-His-Pro-Asn-Ile-Pro-Gly-Leu-Xaa2-Tyr-Phe), wherein Xaa1 is any one selected from the group consisting of tyrosine, tryptophan, phenylalanine and non-natural amino acids having characteristics identical to tyrosine, tryptophan or phenylalanine; and Xaa2 is any one selected from the group consisting of tyrosine, tryptophan, phenylalanine, and non-natural amino acids having the characteristics identical to tyrosine, tryptophan or phenylanine is described.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: February 18, 2020
    Inventor: Brian Byeoung Kim
  • Patent number: 10562966
    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: February 18, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Paul Humphreys, Shirley Jane Peters, Ralph Adams, James Heads
  • Patent number: 10548895
    Abstract: The invention pertains to ligands that bind to CD81 and that inhibit or block Plasmodium attachment to CD81, compositions and methods for preventing, inhibiting or treating infection by Plasmodium and ligands that target a Plasmodium binding site on CD81 and methods of making and using them. A series of ligand binding sites on the large extracellular loop of the open conformation of CD81 have been identified. Several important sites were located in regions identified by mutational studies to be the site of Plasmodium binding. Ligands that recognize these sites were identified. Linking together two or three ligands that bind with low or moderate affinities to different structurally unique sites on a target protein were used to generate small molecule ligand conjugates that exhibit very high affinities to their CD81 targets. Hybrid ligand molecules were also designed using fragment-based drug design methods to generate analogs of the ligands that bind more tightly to the protein than the parent compounds.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: February 4, 2020
    Assignee: The American University in Cairo
    Inventors: Hassan Azzazy, Reem Al-Olaby, Rodney Balhorn
  • Patent number: 10538587
    Abstract: The present disclosure relates to antibodies or fragments thereof that target at least one conformational epitope of a Notch 3 or mutant Notch 3 receptor; and compositions and methods of use thereof.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: January 21, 2020
    Assignee: Novartis AG
    Inventors: Joelle Deplazes-Lauber, Christy Fryer, Tiacen Hu, David Jenkins, Konstantin Petropoulos, Philippe Thiel
  • Patent number: 10538575
    Abstract: There are described herein novel soluble IGF receptor Fc fusion proteins and compositions and methods of use thereof for treating angiogenesis associated disorders and malignant disease, such as cancer and metastasis, wherein the fusion proteins bind specifically to IGF-1 or IGF-2.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: January 21, 2020
    Inventors: Pnina Brodt, Bernard Massie, Traian Sulea
  • Patent number: 10533161
    Abstract: A NADPH oxidase (Nox) protein includes a domain including 3 to 7 transmembrane helices, and an amino acid sequence including at least 2 bis-histidyl motifs, wherein each of the bis-histidyl motifs consists of 2 histidine residues separated by 12, 13 or 14 amino acid residues. The Nox protein may be produced by a method that includes solubilizing a solution of cells expressing the Nox protein using a detergent from the maltoside family to suspend the Nox protein in the solution.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: January 14, 2020
    Assignees: UNIVERSITE GRENOBLE ALPES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jérôme Dupuy, Christine Hajjar, Mickaël Cherrier, Franck Fieschi
  • Patent number: 10524473
    Abstract: Disclosed are peptides that induce an active plant response, but not a hypersensitive response, when applied to plant tissue. These peptides also preferably exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: January 7, 2020
    Assignee: Plant Health Care, Inc.
    Inventors: Zhongmin Wei, Gregory A. Zornetzer
  • Patent number: 10526391
    Abstract: Molecular constructs and dual recognition constructs having a sequence encoding a TCR affinity weakening motif, and DNA and RNA sequences corresponding thereto, are presented. Modified T-cells and other cells transformed with the molecular contracts express a modified TCR that imparts a reduction, in non-specific binding, -an enhancement of binding specificity and an enhancement of binding affinity for a target antigen, compared to non-transformed (wild-type, native) T-cells, are described. The modified TCRs possess an affinity enhancing motif and an affinity weakening motif. Methods of transforming cells and methods of using enriched populations of transformed cells, in the treatment of cancer and infections arid T-cell mediated pathologies are provided. The affinity weakening motif imparts a weakened interaction, of a TCR with major histocompatibility complex proteins, such as HLA proteins in humans.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: January 7, 2020
    Assignees: The University of Notre Dame du Lac, University of Massachusetts
    Inventors: Brian Baker, Lance Hellman, Brian Pierce, Zhiping Weng
  • Patent number: 10513563
    Abstract: The present invention provides compositions useful as prodrugs and methods for making the same. The compositions include a fusion protein having a first delivery domain and a second protein precursor domain linked together via a linker sequence. The delivery domain is a protein capable of facilitating entry to a target cells via the endocytotic pathway, such as transferrin. The protein precursor is a prohormone or a profactor, such as proinsulin. Methods of this invention include the steps of selecting a protein suitable as the delivery domain, constructing a vector to encode the fusion protein, and expressing the fusion protein in a suitable expression host. Also disclosed is a method for targeted-delivery of prodrugs to livers and a method of reducing hepatic glucose production.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: December 24, 2019
    Assignee: University of Southern California
    Inventors: Wei-Chiang Shen, Yan Wang, Jennica Krankel
  • Patent number: 10508136
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: December 17, 2019
    Assignee: TEL HASHOMER MEDICAL RESEARCH, INFRASTRUCTURE AND SERVICES LTD.
    Inventor: Amir Zlotkin
  • Patent number: 10501520
    Abstract: B7-H5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: December 10, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Lieping Chen
  • Patent number: 10465000
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: November 5, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • Patent number: 10448662
    Abstract: The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 22, 2019
    Assignees: Y-Biologics Inc., Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Young Woo Park, Bum-chan Park, Bong-soo Cha, Yong Ho Lee, Jung Chae Lim, Young-gyu Cho, Joong Kyu Kim, Jae Eun Park, Seok Ho Yoo
  • Patent number: 10450380
    Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: October 22, 2019
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Patent number: 10428337
    Abstract: Provided are constructs and methods for expressing a transgene in plant cells and/or plant tissues using gene regulatory elements obtained from Brassica napus.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: October 1, 2019
    Assignee: Dow AgroSciences LLC
    Inventors: Holly Jean Butler, Scott Alan Bevan, Cory M. Larsen, William Moskal, Delkin Orlando Gonzalez
  • Patent number: 10428305
    Abstract: The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 1, 2019
    Assignees: National University of Singapore, St. Jude Children's Research Hospital, Inc.
    Inventors: Dario Campana, David Shook, Masaru Imamura
  • Patent number: 10428137
    Abstract: The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc. Disclosed are furthermore novel protein or peptide structures, nucleic acids encoding same and cloning and expression vectors suitable for carrying out the inventive method for assembling multimeric proteins or peptides.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: October 1, 2019
    Assignee: ALBERT-LUDWIGS-UNIVERSITAT FREIBURG
    Inventors: Stefan Schiller, Matthias Huber
  • Patent number: 10421808
    Abstract: The present disclosure provides Bak binding proteins that change the conformation of Bak and uses thereof.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: September 24, 2019
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Amber Alsop, Khatira Anwari, Grant Dewson, Sweta Iyer, Ruth Kluck
  • Patent number: 10421791
    Abstract: The present invention is directed to vegetative insecticidal proteins (Vips) modified to comprise heterologous carbohydrate binding modules and methods of use thereof.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: September 24, 2019
    Assignee: Syngenta Participations AG
    Inventor: Joseph M. Watts
  • Patent number: 10406214
    Abstract: This invention provides compositions of human propionyl-CoA carboxylase (PCC) and pharmaceutical compositions of human PCC and methods for treating conditions such as propionic acidemia (PA), propionic aciduria, propionyl-CoA carboxylase deficiency and ketotic glycinemia.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: September 10, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventor: Jan P. Kraus
  • Patent number: 10400257
    Abstract: One aspect of the invention relates to a mutant polypeptide comprising the amino acid sequence of Escherichia coli tetracycline efflux pump A (TetA). Another aspect of the invention relates to a polynucleotide encoding a polypeptide of TetA, a fragment thereof, or a mutant thereof. Another aspect of the invention relates to a first expression plasmid vector comprising one or more first polynucleotides encoding a first polypeptide comprising a tetracycline efflux pump polypeptide, a fragment thereof or a mutant thereof, one or more second polynucleotides independently selected from the group consisting of a third polynucleotide encoding a third polypeptide comprising a lysine decarboxylase polypeptide, a fragment thereof or a mutant thereof, and a fourth polynucleotide encoding a fourth polypeptide comprising a lysine biosynthesis polypeptide, a fragment thereof or a mutant thereof.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: September 3, 2019
    Assignees: CATHAY R&D CENTER CO., LTD, CIBT AMERICA INC.
    Inventors: Howard Chou, Xiucai Liu
  • Patent number: 10385120
    Abstract: The invention relates to a molecular complex for targeting the antigen towards cells comprising antigens, including at least one antigen associated with at least two ligands of surface molecules of cells comprising antigens, said complex including at least one first ligand of a sulphated sugar of the glycosaminoglycan family and a second ligand of a specific surface molecule of cells comprising antigens, and said first ligand being covalently bonded with said antigen and/or said second ligand.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: August 20, 2019
    Assignee: Commissariat a l'Energie Atomique
    Inventors: Michel Leonetti, Alexandra Savatier, Adeline Gadzinski, Jean-Claude Boulain
  • Patent number: 10377808
    Abstract: The present invention pertains to novel high avidity antigen recognizing constructs, such as antibodies or T cell receptors, which specifically bind to the melanoma associated antigen (MAGE) A1. The constructs of the invention are particularly useful for the diagnosis, prevention or therapy of tumorous diseases which are characterized by the specific expression of the MAGE-A1 antigen. Furthermore provided are nucleic acids, vectors and host cells—such as CD4 or CD8 positive T cells—which encode, comprise or present the antigen recognizing constructs of the invention. The invention thus provides new means for immune therapy, specifically adoptive T cell therapy, for treating cancer.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: August 13, 2019
    Assignee: Max-Delbrück-Centrum Für Molekulare Medizin (MDC) Berlin-Buch
    Inventors: Thomas Blankenstein, Matthias Obenaus, Catarina Leitão
  • Patent number: 10369204
    Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: August 6, 2019
    Assignee: Dako Denmark A/S
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 10358472
    Abstract: High affinity CD47 reagents are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for a SIRP? relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity CD47 reagent, which blocks the physiological binding interaction between SIRP? and a ligand, e.g., native CD47.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: July 23, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Chia Chi Ho, Kenan Christopher Garcia, Aaron Michael Ring, Kipp Andrew Weiskopf, Irving L. Weissman, Nan Guo Ring
  • Patent number: 10350216
    Abstract: The present invention relates to preventing and treating leukemia and diseases and disorders of the blood, by inhibiting canonical Wnt signaling in the osteoblasts. The inhibition is accomplished by blocking specific molecules and receptors in the pathway. The present invention also relates to a method of diagnosing leukemia and disorders of the blood, and methods and assay for drug screening and basic research.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: July 16, 2019
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Stavroula Kousteni
  • Patent number: 10344074
    Abstract: The present invention relates to T cell receptors (TCRs) which bind the HLA-A2 restricted FMNKFIYEI (158-166) peptide epitope derived from ? Fetoprotein (AFP). Certain preferred TCRs of the invention demonstrate excellent binding characteristics and specificity profiles for this AFP epitope. T cell receptors of the invention may comprise at least one TCR alpha chain variable domain and/or at least one TCR beta chain variable domain, the alpha chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID No: 2, and/or the beta chain variable domain which may comprise an amino acid sequence that has at least 90% identity to the sequence of amino acid residues 1-112 of SEQ ID No: 3.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: July 9, 2019
    Assignee: ADAPTIMMUNE LIMITED
    Inventors: Peter Molloy, Nicholas Pumphrey
  • Patent number: 10336799
    Abstract: The present invention provides FGF-2 polypeptides that differ from the wild-type FGF-2 (SEQ ID NO:1) at least at amino acid position 56, 102 and 119, wherein the differences are Q56I, N102G, K119N substitutions, leading to FGF-2 polypeptides with higher thermostability, higher biological activity and higher resistance to proteolytic degradation. These polypeptides can be used in cell culture media.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: July 2, 2019
    Assignee: Miltenyi Biotec GmbH
    Inventor: Volker Nolle
  • Patent number: 10336808
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: July 2, 2019
    Assignee: Dako Denmark A/S
    Inventors: Jøgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 10308702
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: June 4, 2019
    Assignee: Bristol-Myers Squibb Comapny
    Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
  • Patent number: 10308984
    Abstract: Nucleic acids sequences that can be used for nucleic acid amplification, for example quantitative nucleic acid amplification, are provided herein.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: June 4, 2019
    Assignee: BECTON, DICKINSON AND COMPANY
    Inventors: Keith Edward Thornton, Danielle Koffenberger, Paul Madepogu
  • Patent number: 10308710
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 4, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • Patent number: 10251941
    Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: April 9, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio
  • Patent number: 10233228
    Abstract: The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: March 19, 2019
    Assignee: ALBUMEDIX LTD
    Inventors: Andrew Plumridge, Darrell Sleep, Inger Sandlie, Jan Terje Andersen, Jason Cameron, Leslie Evans, Steven Athwal, Elizabeth Allan, Esben Peter Friis
  • Patent number: 10227386
    Abstract: Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: March 12, 2019
    Assignee: Entos Pharmaceuticals Inc.
    Inventors: Roy Duncan, Eileen Kathryn Clancy, John Lewis, Roberto Justo De Antueno, Rae-Lynn Nesbitt
  • Patent number: 10226431
    Abstract: Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: March 12, 2019
    Assignee: REBIOTIX, INC.
    Inventors: Lee A. Jones, Courtney R. Jones, Beth Anne-Szkudlarek Brown, Joshua Erickson
  • Patent number: 10221222
    Abstract: Antimicrobial agents, including antimicrobial peptides (AMPs) and uses thereof. Compositions and methods of using dermaseptin-type and piscidin-type antimicrobial peptides that demonstrate activity and improved therapeutic indices against microbial pathogens. The peptide compositions demonstrate the ability to not only maintain or improve antimicrobial activity against bacterial pathogens including Gram-negative microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa, but also significantly decrease hemolytic activity against human red blood cells. Specificity determinants within the AMPS change selectivity from broad spectrum antimicrobial activity to AMPS with gram-negative selectivity.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: March 5, 2019
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Ziqing Jiang, Robert S. Hodges, Lajos Gera, Colin T. Mant